Curevac Nv Stock Filter Stocks by Fundamentals
| CVAC Stock | USD 2.95 0.18 5.75% |
CureVac NV fundamentals help investors to digest information that contributes to CureVac NV's financial success or failures. It also enables traders to predict the movement of CureVac Stock. The fundamental analysis module provides a way to measure CureVac NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CureVac NV stock.
CureVac | Shares Owned by Insiders |
CureVac NV Current Valuation Drivers
We derive many important indicators used in calculating different scores of CureVac NV from analyzing CureVac NV's financial statements. These drivers represent accounts that assess CureVac NV's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CureVac NV's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 9.3B | 8.8B | 5.6B | 1.1B | 841.1M | 799.1M | |
| Enterprise Value | 9.3B | 7.5B | 4.9B | 614.9M | 480.2M | 456.2M |
CureVac NV Institutional Holders
Institutional Holdings refers to the ownership stake in CureVac NV that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CureVac NV's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CureVac NV's value.| Shares | Junked Platinum Investment Management Ltd | 2023-12-31 | 497.9 K | Eversept Partners, Llc | 2023-12-31 | 496.9 K | Norges Bank | 2023-12-31 | 308.7 K | Credit Suisse First Boston (csfb) | 2023-12-31 | 303.9 K | Adage Capital Partners Gp Llc | 2023-12-31 | 248.4 K | Geode Capital Management, Llc | 2023-12-31 | 202 K | Swiss National Bank | 2023-12-31 | 198.5 K | Susquehanna International Group, Llp | 2023-12-31 | 178.2 K | Ubs Group Ag | 2023-12-31 | 131.9 K | Citadel Advisors Llc | 2023-09-30 | 3.1 M | Ra Capital Management, Llc | 2023-12-31 | 2.7 M |
CureVac Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.64) % | ||||
| Current Valuation | 340.46 M | ||||
| Shares Outstanding | 224.31 M | ||||
| Shares Owned By Insiders | 45.30 % | ||||
| Shares Owned By Institutions | 23.77 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 15.20 X | ||||
| Revenue | 52.66 M | ||||
| Gross Profit | (91.55 M) | ||||
| EBITDA | (249.55 M) | ||||
| Net Income | (254.83 M) | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 41.86 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 2.31 X | ||||
| Cash Flow From Operations | (262.4 M) | ||||
| Short Ratio | 5.39 X | ||||
| Earnings Per Share | (1.26) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 9.13 | ||||
| Number Of Employees | 999 | ||||
| Beta | 2.51 | ||||
| Market Capitalization | 702.08 M | ||||
| Total Asset | 788.9 M | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 291.99 M | ||||
| Net Asset | 788.9 M |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with CureVac NV
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CureVac NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will appreciate offsetting losses from the drop in the long position's value.Moving together with CureVac Stock
| 0.79 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.82 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against CureVac Stock
| 0.81 | QLI | Qilian International | PairCorr |
| 0.74 | SNDL | SNDL Inc Financial Report 20th of May 2024 | PairCorr |
| 0.71 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.6 | IMCC | Im Cannabis Corp | PairCorr |
| 0.5 | UPC | Universe Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to CureVac NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CureVac NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CureVac NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CureVac NV to buy it.
The correlation of CureVac NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CureVac NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CureVac NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CureVac NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CureVac NV Piotroski F Score and CureVac NV Altman Z Score analysis. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets |
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.243 | Quarterly Revenue Growth 0.931 | Return On Assets (0.21) | Return On Equity (0.50) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.